Nicholas Hoffman & Company
VRTX icon

Nicholas Hoffman & Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Nicholas Hoffman & Company’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$387K Buy
740
+2
+0.3% +$1.02K 0.01% 265
2026
Q2 		$367K Buy
738
+6
+0.8% +$2.66K 0.01% 274
2026
Q1 		$327K Hold
732
– – 0.01% 278
2025
Q4 		$332K Hold
732
– – 0.01% 265
2025
Q3 		$287K Hold
732
– – 0.01% 267
2025
Q2 		$326K Hold
732
– – 0.01% 246
2025
Q1 		$355K Hold
732
– – 0.01% 229
2024
Q4 		$295K Hold
732
– – 0.01% 242
2024
Q3 		$340K Sell
732
-100
-12% -$48K 0.01% 236
2024
Q2 		$390K Buy
832
+100
+14% +$43.4K 0.02% 217
2024
Q1 		$306K Buy
732
+96
+15% +$40.6K 0.02% 238
2023
Q4 		$259K Buy
636
+24
+4% +$8.87K 0.02% 247
2023
Q3 		$213K Hold
612
– – 0.02% 256
2023
Q2 		$215K Sell
612
-289
-32% -$97.4K 0.01% 255
2023
Q1 		$284K Hold
901
– – 0.03% 225
2022
Q4 		$260K Hold
901
– – 0.03% 227
2022
Q3 		$261K Hold
901
– – 0.01% 216
2022
Q2 		$254K Buy
901
+17
+2% +$4.55K 0.01% 223
2022
Q1 		$231K Buy
+884
New +$210K 0.01% 258

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Nicholas Hoffman & Company's VRTX Position: Q3 2026 in Review

Nicholas Hoffman & Company increased its Vertex Pharmaceuticals (VRTX) stake by 0.27% in Q3 2026, buying an estimated $1.02K and bringing the position to 740 shares worth $387K. The position accounts for 0.01% of the portfolio, ranked #265.

Nicholas Hoffman & Company first reported a position in VRTX in Q1 2022 and has held it in 19 quarters since. The position peaked at $390K in Q2 2024. 1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Nicholas Hoffman & Company held 740 shares of Vertex Pharmaceuticals worth $387K as of Q3 2026.
  • Nicholas Hoffman & Company bought 2 Vertex Pharmaceuticals shares in Q3 2026, an estimated $1.02K.
  • Vertex Pharmaceuticals made up 0.01% of Nicholas Hoffman & Company's portfolio in Q3 2026, its #265 holding.
  • Nicholas Hoffman & Company first reported a position in Vertex Pharmaceuticals in Q1 2022 and has held it in 19 quarters since.
  • Nicholas Hoffman & Company's Vertex Pharmaceuticals position peaked at $390K in Q2 2024.
  • 1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Nicholas Hoffman & Company's 13F filing for Q3 2026, filed 30 Oct 2026.